BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. The company is headquartered in Mainz, Rheinland-Pfalz and currently employs 6,772 full-time employees. The company went IPO on 2019-10-10. The firm focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The firm is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. The company also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Follow-Up Questions
¿Qué tal es el rendimiento del precio de la acción BNTX?
El precio actual de BNTX es de $104.21, ha decreased un 0.58% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Biontech SE?
Biontech SE pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de Biontech SE?
La capitalización bursátil actual de Biontech SE es $25.0B
¿Es Biontech SE una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 24 analistas han realizado calificaciones de análisis para Biontech SE, incluyendo 7 fuerte compra, 14 compra, 7 mantener, 0 venta, y 7 fuerte venta
